ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Nxera Pharma Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.54%
2
Flat results in Mar 26
- NET PROFIT(HY) At JPY -5,928 MM has Grown at -182.96%
- INTEREST(HY) At JPY 6,051 MM has Grown at 1,235.76%
- ROCE(HY) Lowest at -15.26%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 4.26%, its profits have fallen by -159%
4
Underperformed the market in the last 1 year
- The stock has generated a return of 4.26% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 85.83%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Nxera Pharma Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Nxera Pharma Co., Ltd.
4.26%
79.63
49.55%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
27.35%
EBIT Growth (5y)
-257.53%
EBIT to Interest (avg)
-1.07
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
0.21
Tax Ratio
42.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.52%
ROE (avg)
1.54%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.36
EV to EBIT
-14.07
EV to EBITDA
-29.79
EV to Capital Employed
1.23
EV to Sales
3.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.76%
ROE (Latest)
-20.54%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -19.25% (YoY
NET SALES(Q)
Highest at JPY 11,256 MM
OPERATING PROFIT(Q)
Highest at JPY 4,641 MM
OPERATING PROFIT MARGIN(Q)
Highest at 41.23 %
PRE-TAX PROFIT(Q)
Highest at JPY 3,100 MM
NET PROFIT(Q)
Highest at JPY 1,793 MM
EPS(Q)
Highest at JPY 17.13
-23What is not working for the Company
NET PROFIT(HY)
At JPY -5,928 MM has Grown at -182.96%
INTEREST(HY)
At JPY 6,051 MM has Grown at 1,235.76%
ROCE(HY)
Lowest at -15.26%
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.77 times
CASH AND EQV(HY)
Lowest at JPY 31,962 MM
DEBT-EQUITY RATIO
(HY)
Highest at 69.45 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.41 times
Here's what is working for Nxera Pharma Co., Ltd.
Net Sales
At JPY 11,256 MM has Grown at 69.42%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (JPY MM)
Pre-Tax Profit
At JPY 3,100 MM has Grown at 243.78%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 1,793 MM has Grown at 335.92%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Net Sales
Highest at JPY 11,256 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 4,641 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 41.23 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 3,100 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 1,793 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 17.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by -19.25% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Nxera Pharma Co., Ltd.
Interest
At JPY 6,051 MM has Grown at 1,235.76%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Inventory Turnover Ratio
Lowest at 0.77 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Cash and Eqv
Lowest at JPY 31,962 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 69.45 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 3.41 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
